Abstract:Abstract Background Malic enzyme 1 (ME1) catalyzes malate to pyruvate and thus promotes glycolysis, playing a part in the Warburg effect. It also has a potential role in tumor progression, but its function in breast cancer remains to be fully clarified. This work aimed to investigate the prognostic value of ME1 and its possible mechanism in breast cancer.Methods We evaluated ME1 expression in 220 early breast cancer patients with tissue microarray-based immunohistochemistry and explored the relationships between ME1 expression and clinicopathological features. Survival analyses were further performed to determine its prognostic value. The public database was used to confirm tissue microarray results. Moreover, we profiled ME1 expression in breast cancer cell lines via western blotting, and then assessed it in cell viability and motility via Cell counting kit-8 (CCK-8), colony formation, transwell migration and invasion assays. Reactive oxygen species (ROS) was detected by dihydroethidium (DHE) and 2’,7’-Dichlorodihydrofluorescein diacetate (DCFH-DA).Results In breast cancer tissues, high ME1 expression was significantly associated with larger tumor size, more lymph node metastasis and more extensive lymph-vascular invasion. Survival analysis showed high ME1 expression was significantly correlated with worse recurrence free survival (RFS). Multivariate analysis further identified high ME1 expression as an independent prognostic factor for RFS, which was confirmed by mRNA results in the public database. In vitro , human epidermal growth factor receptor-2 positive and triple negative breast cancer cell lines showed higher expression of ME1, while Luminal cell lines showed lower expression of ME1. Upregulation of ME1 by transfecting MCF-7 cells with virus vector remarkably enhanced viability and motility, epithelial-mesenchymal transition (EMT), and decreased ROS levels, whereas knockdown of this gene in MDA-MB-468 cells produced totally opposite effects as expected. More important, when pretreated with hydrogen peroxide, an oxidizing agent, MCF-7 cells overexpressing ME1 lost its motility, whereas MDA-MB-468 cells with knock-down of ME1 restored its motility when pretreated with N-acetyl cysteine, an antioxidant.Conclusions To our knowledge, these clinical and experiment work first suggested that ME1 may be a potential therapeutic target for breast cancer metastasis, and its biological effect is mainly controlled by manipulating ROS.

Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions

Malic enzyme 1 (ME1) in the biology of cancer: it is not just intermediary metabolism.

Repressing Malic Enzyme 1 Redirects Glucose Metabolism, Unbalances the Redox State, and Attenuates Migratory and Invasive Abilities in Nasopharyngeal Carcinoma Cell Lines

Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.

Malic enzyme 1 may be a novel target of breast cancer metastasis

Expression of cytosolic malic enzyme (ME1) is associated with disease progression in human oral squamous cell carcinoma

Malic enzyme 1 induces epithelial–mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma

Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions

Malic enzyme 1 knockout has no deleterious phenotype and is favored in the male germline under standard laboratory conditions

Overexpression of malic enzyme is involved in breast cancer growth and is correlated with poor prognosis

Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis.

Malic Enzyme 1 (ME1) is pro-oncogenic in ApcMin/+ mice

Malic Enzyme 1 Indicates Worse Prognosis in Breast Cancer and Promotes Metastasis by Manipulating Reactive Oxygen Species

Mitochondrial Pyruvate Carrier 1: a Novel Prognostic Biomarker That Predicts Favourable Patient Survival in Cancer

O-GlcNAcylation Promotes Pancreatic Tumor Growth by Regulating Malate Dehydrogenase 1

Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactions

Malic enzyme 1 (ME1) is a potential oncogene in gastric cancer cells and is associated with poor survival of gastric cancer patients

ME1 promotes basal-like breast cancer progression and associates with poor prognosis

Malic Enzyme 1 as a Novel Anti‐Ferroptotic Regulator in Hepatic Ischemia/Reperfusion Injury

Malic Enzyme 2 Maintains Metabolic State and Anti-Tumor Immunity of CD8+ T Cells